Nkwupụta: Ezigbo ihe mere ị ga-eji zuo ike. Nnyocha ndị ọzọ egosiwo na ụra adịghị ehi ụra, nke nwere ike ibute ya na ndị na-anabata dopamine D2.
Ihe akaebe na nkwụsị ụra na-agbanwe Dopamine D2R na Ventral Striatum na Brain Mmadụ.
J Neurosci. 2012 Ka 9; 32 (19): 6711-7.
Volkow ND, Tomasi D, Wang GJ, Telang F, Fowler JS, Logan J, Benveniste H, Kim R, Thanos PK, Ferré S.
nkịtị
Dopamine D2 ndị nabatara gụnyere ịmụrụ anya, mana ọrụ ha na mbelata nchedo metụtara ụra ụra edoghị anya. Anyị egosila na ụra ụra belatara nnweta nnabata dopamine D2 / D3 (nke ejiri PET na [(11) C] raclopride na njikwa) na striatum, mana enweghị ike ịchọpụta ma nke a gosipụtara mmụba dopamine ([11) C] raclopride na-asọ mpi dopamine maka ihe ntinye aka na D2 / D3) ma ọ bụ nchịkwa nchịkwa. Iji mee ka nke a doo anya, anyị jiri mmụba dopamine na-ebute site na methylphenidate (ọgwụ na-eme ka dopamine site na igbochi ndị na-ebugharị dopamine) n'oge ụra ụra na ụra ụra, na-eche na mmetụta methylphenidate ga-aka ukwuu ma ọ bụrụ na, n'ezie, ntọhapụ dopamine mụbara n'oge ụra ụra . Anyị nyochara njikwa 20 na [(11) C] raclopride mgbe ụra zuru ike na mgbe 1 abalị ụra na-ehi ụra; ma mgbe placebo na mgbe methylphenidate. Anyị mere ka ọnụ ọgụgụ dị na D2 / D3 dị na ventral striatum na njedebe ụra (ma e jiri ya tụnyere ụra ezumike) nke ejikọtara ya na nchebe dị ala na ụba ụra. Otú ọ dị, dopamine na-arịwanye elu site na methylphenidate (atụle dịka nbelata na nnweta nnweta nke nnweta nke D2 / D3 ma tụnyere placebo) adịghị iche n'etiti ụra ezumike na ụra na-ehi ụra, ma jikọtara ya na ụba amụba ma belata ụra mgbe a na-eduzi methylphenidate mgbe ụra na-ehi ụra. Enwetara ihe ndị yiri nke ahụ site na microdialysis na òké ndị e mere ka abalị 1 nke ụra na-atụ egwu. Nchọpụta ndị a na-adabere nchịkwa nke ndị nzaghachi D2 / D3 na ventral striatum na nhụhụhụ ụra nke nwere ike inye aka na njikọ ahụ na-ebelata ahazi ma mee ka mmezi nke D2 na-egosi na mmetụta mgbu nke methylphenidate n'ime ụmụ mmadụ.
;